RCSB PDB - 2VIO: Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator (original) (raw)
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator
[Frederickson, M.](/search?q=citation.rcsb%5Fauthors:Frederickson, M.), [Callaghan, O.](/search?q=citation.rcsb%5Fauthors:Callaghan, O.), [Chessari, G.](/search?q=citation.rcsb%5Fauthors:Chessari, G.), [Congreve, M.](/search?q=citation.rcsb%5Fauthors:Congreve, M.), [Cowan, S.R.](/search?q=citation.rcsb%5Fauthors:Cowan, S.R.), [Matthews, J.E.](/search?q=citation.rcsb%5Fauthors:Matthews, J.E.), [Mcmenamin, R.](/search?q=citation.rcsb%5Fauthors:Mcmenamin, R.), [Smith, D.](/search?q=citation.rcsb%5Fauthors:Smith, D.), [Vinkovic, M.](/search?q=citation.rcsb%5Fauthors:Vinkovic, M.), [Wallis, N.G.](/search?q=citation.rcsb%5Fauthors:Wallis, N.G.)
(2008) J Med Chem 51: 183
PubMed: 18163548 Search on PubMed
PubMed Abstract:
Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
Organizational Affiliation:
Astex Therapeutics Ltd, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, United Kingdom. m.frederickson@astex-therapeutics.com